Founder Insights
Four pillars. One coordinated path.
Explore the developments that could shape your next U.S. decision.
Strategy & Execution
Translate U.S. market and regulatory signals into the next commercialization milestone.
Clinical Evidence
Build evidence that supports regulatory decisions, clinical confidence and adoption.
Strategic Partnerships
Find relevant U.S. clinical, commercial and ecosystem pathways for your product.
Capital
Connect funding routes and investor expectations to credible U.S. milestones.
Lead signal
In this edition
A first look across strategy, evidence, partnerships and capital.
FDA prioritizes medical AI lifecycle and change-control guidance
Japanese medical-AI teams should anticipate evolving documentation and update-management expectations when planning U.S. development milestones.
FDAHome-collected diagnostics: validate the complete testing workflow
Japanese diagnostic teams need evidence across the patient-to-laboratory journey, including whether lay users collect specimens correctly.
FDA / Federal RegisterMedTech Innovator 2027 offers a competitive U.S. partner route
Japanese founders should articulate a specific U.S. use case and partner need before applying.
MedTech InnovatorSofinnova closes €82 million for medtech company creation
Japanese teams considering a U.S. venture should assess how company creation fits their IP and ownership plans.
Sofinnova PartnersBuilt around your next milestone
Each pillar brings together what changed, why it matters and a practical next consideration. Up to five selected signals keep the briefing focused on regulated healthcare commercialization.